UNSPSC 51273601: Bucricaine

This classification denotes an anesthetic agent with the molecular formula C17H22N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HUC352BGYM, chemically known as 1,2,3,4-tetrahydro-n-butyl-9-acridinamine but generally known as bucricaine, which bears US NIH Compound Identifier 9423. European Medicines Agency schedules Bucricaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05951MIG.

UNSPSC 51273601 Bucricaine (Commodity) shows minimal recent state and local procurement activity tied to the code itself; the three recent opportunities posted under this taxonomy span pharmaceutical and health-supply procurement, but none directly name bucricaine as a line item or primary deliverable. Seminole County, Florida's IFB for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023) procures health emergency response supplies through competitive bidding with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (HHS0017013, posted April 3, 2026) seeks vendor capabilities for establishing pharmacy benefit relationships outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) establishes statewide contracts distributed through three authorized wholesalers to government facilities across Minnesota and Oregon, weighted 75 percent on price competitiveness and requiring cGMP and Drug Supply Chain Security Act compliance. The issuing bodies span county health departments (Seminole County), state HHS commissions (Texas), and cooperative purchasing alliances serving multiple states (MMCAP), indicating a mix of direct-procuring health agencies and cooperative purchasing vehicles.

Geographic activity centers on Florida, Texas, and the upper Midwest (Minnesota and Oregon), though the source does not identify bucricaine specifically in any recent solicitation scope. The code's taxonomy placement alongside broader pharmaceutical procurement does not clarify demand for this particular local anesthetic compound. Firms pursuing work in this code should verify current health department inventory requests and cooperative purchasing schedules, as the recent record suggests state and local health procurement is active but the specific product focus remains unclear from available opportunities.